Abigail Brooks, MA

The CRL is consistent with the outcome of a September Gastrointestinal Drugs Advisory Committee meeting.

Alkhouri explains the first real-world data on the use of resmetirom (Rezdiffra) in patients with MASH and how they compare to clinical trial findings.

Treatment with the novel selective endothelin receptor type A antagonist alongside standard care reduced UPCR in patients with IgAN in a phase 2 trial.

Phase 1b data support proof-of-principle for EBX-102 across microbiome and clinical assessments as well as inflammatory biomarkers for cirrhosis.

Braden Kuo, MD, explains how the gas-sensing capsule compares to the FDA-cleared, but now discontinued, SmartPill wireless motility capsule.

The study is one of the first to report United States IgAN incidence based on a large racially and ethnically diverse cohort.

Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.

Findings suggest HS is associated with pregnancy complications and adverse outcomes for both mothers and offspring.

This month in review spotlights HCPLive’s coverage of the ACG 2024 meeting, GI pipeline updates, and other news and research from October.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

Anthony Kerbage, MD, describes disparities in 21 IBS clinical trials whose data was used to support the FDA approvals of 7 IBS-C and IBS-D drugs.

Mohammad Abuassi, MD, explains how classifying IBS based on triggers can aid the development of effective, personalized approaches to management.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.

Rao explains the comparative effectiveness of biofeedback and dextranomer injections for treating fecal incontinence.

Iyer reviews findings from subgroup analyses of the phase 3 STARS study of apraglutide for SBS-IF based on demographics and disease characteristics.

Dellon reviews phase 3 data supporting the 48-week safety and efficacy of cendakimab for treating EoE.

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.

Lacy explains the potential value of an ambulatory wireless patch test for identifying unique gastric activity patterns and individualizing patient care.

Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.

Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.